QR koda

Anlotinib monotherapy in recurrent or metastatic nasopharyngeal carcinoma: a multicenter case-series analysis

Anlotinib has shown encouraging therapeutic effect on various solid tumors. This study assessed the efficacy and safety of anlotinib monotherapy in patients with recurrent or metastatic nasopharyngeal carcinoma (rmNPC).

Shranjeno v:
Principais autores: Qin Guan-Jie, Su Yi-Xin, Liang Yong, Zhang Bin, Pan Yu-Fei, Lu Jian-Xun, Xie Yue-Yun, Dai Jin-Xuan, Chen Ke-Quan, Qin Feng-Fei, Yang Hui-Yun, Kong Xiang-Yun, Xie Yuan, Ruan Xiao-Lan, Mo Yun-Yan, Zhang Ru-Yun, Zhang Jian, Jiang Wei
Format: Artigo
Jezik:Inglês
Izdano: Sciendo 2025-12-01
Serija:Radiology and Oncology
Teme:
anlotinib
nasopharyngeal carcinoma
recurrent
metastasis
tyrosine kinase inhibitors (tki)
Online dostop:https://doi.org/10.2478/raon-2025-0059
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki